Human kallikrein-related peptidase 12: Antibody generation and immunohistochemical localization in prostatic tissues

Prostate

Volumn 67, Issue 13, 2007, Pages 1465-1474

  Memari, Nader ^a,b   Diamandis, Eleftherios P ^a,b   Earle, Tammy ^a   Campbell, Alison ^b   Van Dekken, Herman ^c   Van Der Kwast, Theodore H ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer biomarkers; KLK12; Prostate cancer; Protein expression; Serine proteases

Indexed keywords

KALLIKREIN; KALLIKREIN 12; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; RABBIT; TISSUE MICROARRAY;

ADENOCARCINOMA; ANTIBODIES, NEOPLASM; BLOTTING, WESTERN; DNA, COMPLEMENTARY; ESCHERICHIA COLI; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; MALE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE ARRAY ANALYSIS;

EID: 34548800316     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20596     Document Type: Article

References (53)

1. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol Metab 2000;11:54-60.
2. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 2001;22:184-204.
3. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-890.
4. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: Functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004;41:265-312.
5. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: Applications in cancer. Cancer Lett 2005;224:1-22.
6. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
7. Diamandis EP. Prostate-specific antigen - Its usefulness in clinical medicine. Trends Endocrinol Metab 1998;9:310-316.
8. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368.
9. Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001;49:101-109.
10. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002;59:2-8.
11. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 2003;3:6543-6546.
12. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996;2:624-636.
13. Tanimoto H, Underwood LJ, Shigemasa K, Yan Y, Clarke J, O'Brien TJ. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999;86:2074-2082.
14. Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nicklin J, Samaratunga H, Clements JA. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 2001;7:2363-2371.
15. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: A new independent and favorable prognostic marker. Cancer Res 2001;61:7811-7818.
16. Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, de Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Katsaros D. Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035-1043.
17. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, Van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Diamandis EP. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63:807-811.
18. Ni X, Zhang W, Huang K-C, Wang Y, Ng S-K, Mok SC, Berkowitz RS, Ng SW. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 2004;91:725-731.
19. Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponzone R, Diamandis EP. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: An independent indicator of favourable prognosis in breast cancer. Br J Cancer 2002;86:1457-1464.
20. Luo LY, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer 2002;86:1790-1796.
21. Yousef GM, Borgono CA, Scorilas A, Ponzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P, Diamandis EP. Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br J Cancer 2002;87:1287-1293.
22. Yousef GM, Scorilas A, Kyriakopoulou LG, Rendl L, Diamandis M, Ponzone R, Biglia N, Giai M, Roagna R, Sismondi P, Diamandis EP. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: An independent indicator of poor prognosis in breast cancer. Clin Chem 2002;48:1241-1250.
23. Yousef GM, Scorilas A, Nakamura T, Ellatif MA, Ponzone R, Biglia N, Maggiorotto F, Roagna R, Sismondi P, Diamandis EP. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat 2003;78:149-158.
24. Yunes MJ, Neuschatz AC, Bornstein LE, Naber SP, Band V, Wazer DE. Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery. Int J Radiat Oncol Biol Phys 2003;56:653-657.
25. Talieri M, Diamandis EP, Gourgiotis D, Mathioudaki K, Scorilas A. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: A new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004;91:180-186.
26. Fritzsche F, Gansukh T, Borgono CA, Burkhardt M, Pahl S, Mayordomo E, Winzer KJ, Weichert W, Denkert C, Jung K, Stephan C, Dietel M, Diamandis EP, Dahl E, Kristiansen G. Expression of human kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. Br J Cancer 2006;94:540-547.
27. Chang A, Yousef GM, Jung K, Meyts ER, Diamandis EP. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13;KLK-L4) splice variants: Differential expression in human testis and testicular cancer. Anticancer Res 2001;21:3147-3152.
28. Luo LY, Rajpert-De Meyts ER, Jung K, Diamandis EP. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 2001;85:220-224.
29. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res 2001;61:3425-3431.
30. Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A, Diamandis EP. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology 2002;60:714-718.
31. Luo LY, Yousef GM, Diamandis EP. Human tissue kallikreins and testicular cancer. APMIS 2003;111:225-232.
32. Yousef GM, Borgono CA, White NM, Robb JD, Michael IP, Oikonomopoulou K, Khan S, Diamandis EP. In silico analysis of the human kallikrein gene 6. Tumour Biol 2004;25:282-289.
33. Santin AD, Cane S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Roman JJ, Anfossi S, O'Brien T, Pecorelli S. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecol Oncol 2004;94:283-288.
34. Tian X, Shigemasa K, Hirata E, Gu L, Uebaba Y, Nagai N, O'Brien TJ, Ohama K. Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep 2004;12:1001-1006.
35. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H, Murayama S, Mori M. Clinical significance of human kallikrein gene 6 messenger RNA expression in color-ectal cancer. Clin Cancer Res 2005;11:2889-2893.
36. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, Diamandis EP. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem 2001;49:1431-1441.
37. Petraki CD, Karavana VN, Luo L-Y, Diamandis EP. Human kallikrein 10 expression in normal tissues by immunochistochemistry. J Histochem Cytochem 2002;50:1247-1261.
38. Petraki CD, Karavana VN, Diamandis EP. Human kallikrein 13 expression in normal tissues: An immunohistochemical study. J Histochem Cytochem 2003;51:493-501.
39. Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol Rep 2004;11:1153-1159.
40. Dong Y, Bui LT, Odorico DM, Tan OL, Myers SA, Samaratunga H, Gardiner RA, Clements JA. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: Nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer 2005;12:875-889.
41. Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, Diamandis EP. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6,10 and 11 in renal cell carcinoma. Tumour Biol 2006;27:1-7.
42. Yousef GM, Diamandis EP. The expanded human kallikrein gene family: Locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). Genomics 2000;65:184-194.
43. Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H. New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000;46:1855-1858.
44. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltas LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM. A comprehensive nomenclatures for serine proteases with homology to tissue kallikreins. Biol Chem 2006;387:637-641.
45. Shinmura K, Tao H, Yamada H, Kataoka H, Sanjar R, Wang J, Yoshimura K, Sugimura H. Splice-site genetic polymorphism of the human kallikrein 12 (KLK12) gene correlates with no substantial expression of KLK12 protein having serine protease activity. Hum Mutat 2004; 24:273-274.
46. Yousef GM, Magklara A, Diamandis EP. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 2000;69:331-341.
47. Kurlender L, Borgono C, Michael IP, Obiezu CV, Elliot MB, Yousef GM, Diamandis EP. A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta 2005;1755:1-14.
48. Memari N, Grass L, Nakamura T, Karakucuk I, Diamandis EP. Human kallikrein 9: Production of recombinant proteins and specific antibodies. Biol Chem 2006;387:733-740.
49. Luo LY, Grass L, Howarth DJ, Thibault P, Ong H, Diamandis EP. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 2001;47:237-246.
50. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
51. Li Y, Yu Z, Zhao X, Shen S. Identification and characterization of hepsin/-TM, a non-transmembrane hepsin isoform. Biochim Biophys Acta 2005;1681:157-165.
52. Diamandis EP, Okui A, Mitsui S, Luo L_Y, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N. Human kallikrein 11: A new biomarker of prostate and ovarian cancer. Cancer Res 2002;62:295-300.
53. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Rel Cancer 2005;12:617-629.